Last updated: 2026-09-16 13:20:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
PTC Therapeutics, Inc. (PTCT) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $65,52, with a market capitalisation of $5,55B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $57,74 to $90,87. This page covers its latest market performance, valuation, price trends and company information.
$5,55B | |
$65,66 | |
$90,87 | |
$4,03 | |
$65,65 | |
168,00 | |
1,56M | |
-- | |
$90,87 | |
$57,74 | |
-- | |
-- |
PTC Therapeutics, Inc. (PTCT) is trading at $65,52 in pre-market trading as of 2026-09-16 12:00:00, down 0,21% ($0,14) from the previous close of $65,65
Pre-market trading shows how investors are pricing PTCT before the regular session opens. The current pre-market price is near the previous close, indicating cautious early trading sentiment.
Over the past seven days, PTC Therapeutics, Inc. (PTCT) moved from $69,30 to $65,52, representing a decline of 5,46% ($3,78).
The stock traded between $58,02 and $71,41 during the period. The latest price is near the middle of the 7-day range, indicating strong downward.
The average daily volume was 959,64 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 23,5%
PTCT is currently trading at $65,52, placing it 23,5% of the way from its 52-week low of $57,74 to its 52-week high of $90,87. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 991 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of PTC Therapeutics, Inc. (PTCT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.